A new treatment to improve ovarian cancer therapy by blocking DNA repair mechanisms
The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer
This study is looking at a new drug called GRN-300 to see if it can make existing ovarian cancer treatments work better, especially for patients whose cancer has become resistant to standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10993526 on NIH RePORTER |
What this research studies
This research investigates the use of a drug called GRN-300, which inhibits a specific protein (SIK2) to enhance the effectiveness of existing ovarian cancer treatments like carboplatin and paclitaxel. The study aims to determine the best dose of GRN-300 when used alone and in combination with these therapies. It also explores how GRN-300 can make ovarian cancer cells more sensitive to another treatment called olaparib, particularly in cases where the cancer has developed resistance to standard therapies. By blocking certain DNA repair processes in cancer cells, this approach hopes to improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer, especially those who have shown resistance to standard treatments like carboplatin and paclitaxel.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for ovarian cancer patients, particularly those who have become resistant to current therapies.
How similar studies have performed: Previous research has shown promising results with similar approaches in enhancing treatment sensitivity in cancer therapies, indicating potential for success in this study.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.